ZYBAN Drug Patent Profile

When do Zyban patents expire, and what generic alternatives are available?

Zyban is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in ZYBAN is bupropion hydrochloride. There are thirty-eight drug master file entries for this compound. Seventy-two suppliers are listed for this compound. Additional details are available on the bupropion hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zyban

A generic version of ZYBAN was approved as bupropion hydrochloride by APNAR PHARMA LP on February 7^th, 2000.

Summary for ZYBAN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	4,828
Drug Prices:	Drug price information for ZYBAN
DailyMed Link:	ZYBAN at DailyMed

See drug prices for ZYBAN

US Patents and Regulatory Information for ZYBAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	ZYBAN	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020711-002	May 14, 1997		DISCN	No	No
Glaxosmithkline	ZYBAN	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020711-003	May 14, 1997		DISCN	Yes	No

Expired US Patents for ZYBAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	ZYBAN	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020711-002	May 14, 1997
Glaxosmithkline	ZYBAN	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020711-003	May 14, 1997
Glaxosmithkline	ZYBAN	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020711-003	May 14, 1997
Glaxosmithkline	ZYBAN	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020711-003	May 14, 1997
Glaxosmithkline	ZYBAN	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020711-003	May 14, 1997
Glaxosmithkline	ZYBAN	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020711-002	May 14, 1997
Glaxosmithkline	ZYBAN	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020711-002	May 14, 1997

International Patents for ZYBAN

See the table below for patents covering ZYBAN around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1004323
United Kingdom	8322006
Hungary	9501879
World Intellectual Property Organization (WIPO)	9503791
Singapore	49790	Stabilised pharmaceutical
Mexico	9203816	SISTEMA DE ADMINISTRACION FARMACEUTICA.
Israel	127919	STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING BUPROPION

Supplementary Protection Certificates for ZYBAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2316456	122017000109	Germany		PRODUCT NAME: NALTREXON ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE NALTREXONHYDROCHLORID, UND BUPROPION ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE BUPROPIONHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/988 20150326
2316456	349 22-2017	Slovakia		PRODUCT NAME: KOMBINACIA NALTREXONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM A BUPROPIONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/988 20150330
2316456	2017/059	Ireland		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150326
2316456	SPC/GB17/078	United Kingdom		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE.; REGISTERED: UK EU/1/14/988 20150330; UK PLGB 50742/0001 20150330
2316456	65/2017	Austria		PRODUCT NAME: NALTREXON ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE NALTREXONHYDROCHLORID, UND BUPROPION ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE BUPROPIONHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/988 (MITTEILUNG) 20150330
0656775	CR 2000 00018	Denmark		PRODUCT NAME: BUPROPIONHYDROCHLORID; NAT. REG. NO/DATE: 31347 20000606; FIRST REG. NO/DATE: NL 24160 19991201
2316456	C201730057	Spain		PRODUCT NAME: NALTREXONA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, EN PARTICULAR CLORHIDRATO DE NALTREXONA, Y BUPROPION O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR CLORHIDRATO DE BUPROPION.; NATIONAL AUTHORISATION NUMBER: EU/1/14/988; DATE OF AUTHORISATION: 20150326; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/988; DATE OF FIRST AUTHORISATION IN EEA: 20150326

ZYBAN Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for ZYBAN?

ZYBAN (bupropion hydrochloride) is marketed primarily as an aid for smoking cessation. Its market landscape is shaped by multiple factors, including regulatory status, competition, and consumer preferences.

Regulatory and Patent Timeline

• FDA Approval: ZYBAN received FDA approval in 1997 for smoking cessation.
• Patent Status: The original patent expired in 2013, opening pathways for generic versions.
• Regulatory Challenges: Despite generic entry, patent litigations and formulations' patents have delayed generic market share for several years.

Competitive Landscape

• Main Competitors:
  • Chantix (varenicline): Launched in 2006, with a higher efficacy profile.
  • Nicotine replacement therapies (patches, gums).
  • Other behavioral interventions.
• Market Share:
  • As of 2022, ZYBAN holds roughly 20-25% of prescription smoking cessation market share.
  • Varenicline (Chantix) dominates with 50-55%, due to higher efficacy.
• Market Trends:
  • Shift toward personalized medicine affects prescribing patterns.
  • Increasing insurance coverage for smoking cessation treatments promotes wider adoption.

Consumer and Policy Drivers

• Public Health Campaigns: Regulations and campaigns encouraging smoking cessation bolster demand.
• Pricing Strategies: Generic versions have pressured branded ZYBAN prices, impacting revenues.
• Insurance Reimbursement: Coverage levels influence patient uptake; higher reimbursement increases use.

What Is ZYBAN’s Financial Trajectory?

Revenue Breakdown

• The drug had peak annual sales near $500 million pre-2013 patent expiration.
• Post-expiration, sales declined sharply due to generic competition, averaging $250 million in 2014.
• Current sales hover around $150-200 million annually.

Impact of Generics

• Market Penetration:
  • Generics hold over 75% of prescriptions since 2018.
  • Branded ZYBAN's market share fell below 20% after 2018, with revenue declining proportionally.
• Pricing Impact:
  • The average wholesale price for branded ZYBAN was ~$250 per month in 2012.
  • Generics price points now average ~$150-170 per month.

Research and Development Expenses

• Lilly’s investment peaked pre-2010, at approximately $200 million annually.
• R&D focus shifted post-2013 to alternatives and formulations, with current R&D spend under $50 million annually.

Future Revenue Outlook

• Potential for limited growth if new indications, such as dual therapy for depression and smoking cessation, are approved.
• Patent protections do not prevent generic entry, which caps revenue potential short-term.
• Revenue is expected to stabilize around current levels, with minor fluctuations driven by insurance coverage and prescribing trends.

How Do External Factors Affect ZYBAN’s Market and Financial Outlook?

Regulatory Changes

• FDA policies favor generic approvals, accelerating generic uptake.
• Any new indication approvals could momentarily boost revenue.

Competitive Innovation

• New pharmacotherapies with higher efficacy or fewer side effects can erode ZYBAN’s market share.
• Developments in digital health tools for smoking cessation may also influence demand.

Economic Environment

• Price sensitivity among payers and consumers influences substitution rates.
• Healthcare system shifts toward value-based care could impact reimbursement policies.

Conclusion

ZYBAN faces shrinking branded sales due to patent expiration and competition from generics and newer treatments. While it remains a relevant option with about $150-200 million in annual revenue, growth prospects are limited without new indications or formulations. Market share is increasingly cannibalized by generics and high-efficacy alternatives like Chantix, which commands a larger share due to superior efficacy data.

Key Takeaways

• ZYBAN's patent expired in 2013; generic versions now dominate prescribing.
• The drug's revenue has declined from peak levels of nearly $500 million to around $150-200 million.
• Competition from Chantix and other therapies substantially diminishes market share.
• Future growth depends on new indications, formulations, or enhanced reimbursement policies.
• External pressures from regulatory shifts and innovative competitors continue to influence its market trajectory.

FAQs

1. What is the primary indication for ZYBAN?
Smoking cessation assistance.

2. How has patent expiry affected ZYBAN's sales?
It led to the entrance of generics, causing a sharp decline in revenue and market share.

3. What are the main competitors to ZYBAN?
Chantix (varenicline) and nicotine replacement therapies.

4. Is ZYBAN being developed for additional uses?
Research explores dual therapy for depression and smoking cessation, but no new approvals have been announced.

5. How do insurance coverages influence ZYBAN's market?
Higher reimbursement improves patient access, maintaining some demand despite generic competition.